Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Alisusha; Trueffelpix / shutterstock.com

3 New Vasculitis Guidelines Discussed

Ruth Jessen Hickman, MD  |  May 13, 2021

The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:AAV FocusRheumVasculitis Foundation

Case Report: Rapidly Progressive Interstitial Lung Disease in a 6-Year-Old

Anusha Vuppala, MD, & Sarwat Umer, MD  |  April 17, 2021

Clinically amyopathic dermatomyositis (CADM), a rare subset of dermatomyositis (DM), is an autoimmune disease characterized by cutaneous findings of typical DM without evidence of myositis. Childhood presentation of CADM is rare, and not many studies describe the epidemiology of juvenile CADM.1,2 Although lung disease is rare among patients with juvenile DM, a few reports have…

Filed under:ConditionsMyositis Tagged with:Clinically Amyotrophic Dermatomyositis (CADM)dermatomyositisinterstitial lung disease (ILD)juvenile dermatomyositisPediatric Rheumatology

14 Rheumatology Treatments Make Top 50 List of Drugs That Can Cause Anaphylaxis

Michele B. Kaufman, PharmD, BCGP  |  April 15, 2021

A recent study of data from the FDA’s Adverse Event Reporting System reveals that 14 drugs commonly prescribed by rheumatologists are on the list of the top 50 drugs that can cause anaphylaxis.

Filed under:Drug Updates Tagged with:anaphylaxisFDAMedwatchU.S. Food and Drug Administration (FDA)

COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

Marilynn Larkin  |  March 29, 2021

NEW YORK (Reuters Health)—U.K. experts propose evidence-based management strategies for rheumatology patients on immunosuppressive therapy, including delaying/postponing rituximab, as appropriate. “The aim of this viewpoint article is to outline the existing data on the effect of anti-rheumatic therapy on vaccine responses in patients with inflammatory arthritis and to formulate a possible pragmatic strategy for the…

Filed under:Conditions Tagged with:COVID-19immunosuppressive therapyrituximabU.K.vaccination

New Clinical Trials for Ustekinumab & Denosumab Biosimilars Begin Recruitment

Michele B. Kaufman, PharmD, BCGP  |  March 17, 2021

Clinical trials of biosimilar treatments, including a phase 1 study of SB17, which is biosimilar to ustekinumab, and two phase 3 studies investigating of SB16, which is biosimilar to denosumab, are currently recruiting.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsclinical trialsdenosumabSB17ustekinumab

Case Report: A Patient with Submandibular Swelling

Julia A. Ford, MD, Robert Padera, MD, PhD, & Lindsey A. MacFarlane, MD, MPH  |  March 15, 2021

We report on a 77-year-old patient who was diagnosed with giant cell arteritis (GCA) on histopathology of the submandibular gland and eventually went on to develop classic signs and symptoms of GCA. This observation highlights neck swelling as a rare initial presentation of GCA. Case Presentation A 77-year-old previously healthy man presented to his primary…

Filed under:ConditionsVasculitis Tagged with:case reportGiant Cell Arteritissubmandibular swelling

Highlights, Pearls & News from ACR Convergence 2020

Vanessa Caceres  |  March 15, 2021

ACR CONVERGENCE 2020—In a year like no other, the 2020 virtual ACR Convergence was a meeting like no other. Nonetheless, the meeting introduced a healthy mix of clinical insights and take-home pearls, according to panelists in the meeting’s closing session, Bright Future: Discovery & Growth.  In this session, panelists discussed some of the biggest news…

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2020COVID-19Diet

Tips for Balancing Medication Treatment & Risk in Elderly Patients

Thomas R. Collins  |  March 15, 2021

ACR CONVERGENCE 2020—With the inevitable decline in organ function that comes with age, and the likelihood that older patients (i.e., generally defined as older than 60 or 70, depending on the study) are on more than one medication due to multiple comorbidities, therapeutic drug treatment for older patients requires persistent vigilance and know-how, two experts…

Filed under:Conditions Tagged with:ACR Convergence 2020adverse drug reactionelderly

Case Study: Cerebral Toxoplasmosis in a Newly Diagnosed Lupus Patient

Komal Ejaz, MD, & Muhammad Ali Raza, MD  |  March 15, 2021

The occurrence of opportunistic infections is an established complication in patients diagnosed with systemic lupus erythematosus (SLE). The foremost challenge in such circumstances is differentiating between an exacerbation or progression of SLE, and the effects of the infection itself.1 Toxoplasma gondii is a ubiquitous parasite that often causes an asymptomatic infection in healthy, immunocompetent adults….

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportcerebral toxoplasmosisInfectionToxoplasma gondii

In Memoriam: Shunle Chen, MD

Nan Shen, MD, PhD, & Peter E. Lipsky, MD  |  March 15, 2021

It is with great sadness that we report the passing of a giant of international rheumatology, Professor Shunle Chen. He was a friend, colleague, collaborator, visionary leader and inspiration to many rheumatologists in China and the world. Moreover, despite his inter­national stature, he was a warm friend and nurturing mentor to all those who had…

Filed under:Professional TopicsProfiles Tagged with:Dr. Shunle Chen

  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences